As One Of Most Regulated Industries, Health Care Cheers Trump’s One-In, Two-Out Order
The president has mandated that for every regulation an agency adopts it must get rid of two. Although the industry is praising the move, its consequences on Americans' health could be far reaching.
Modern Healthcare:
Healthcare Industry Celebrates 'One-In, Two-Out' Executive Order Despite Unknowns
Healthcare industry stakeholders are lauding President Donald Trump's latest executive order which requires executive departments or agencies to remove at least two previously implemented regulations for every new one issued. The order could have major ramifications for healthcare, one of the most regulated industries in the U.S. economy. Providers and vendors face a myriad of rules drafted by numerous agencies and departments, including the CMS, the Health Resources and Services Administration, the Food and Drug Administration and the Office of the National Coordinator for Health Information Technology. (Rubenfire, 1/30)
Stat:
Trump Order On Regulations May Create Hurdles For FDA, Cures Act
President Trump on Monday signed an executive order directing federal agencies to cut two regulations for every new one that they adopt, a move that could have significant implications for the Food and Drug Administration. Trump, who vowed throughout his campaign to ease the burden of government regulations in order to promote innovation, pledged at the signing ceremony that the order would be “the biggest such act our country has ever seen.” “There will be regulation, there will be control, but it will be normalized control,” he said. (Kaplan, 1/30)
In other administration news —
Stat:
US Health Care, Reliant On Foreign Workers, Struggles With Trump's Ban
President Trump’s temporary immigration ban could quickly undermine American health care, which relies heavily on foreign-born labor — including many workers from the Middle East — to fill critical gaps in care, industry specialists say. As many as 25 percent of physicians practicing in the US were born in another country. Rural clinics and public safety-net hospitals, in particular, rely on foreign medical school graduates to take care of isolated and vulnerable populations. (Ross and Blau, 1/30)
The Wall Street Journal:
Rep. Tom Price Got Privileged, Discounted Offer On Biomedical Stock, Company Says
Rep. Tom Price got a privileged offer to buy a biomedical stock at a discount, the company’s officials said, contrary to his congressional testimony this month. The Georgia Republican tapped by President Donald Trump to be secretary of the Department of Health and Human Services testified in his Senate confirmation hearings on Jan. 18 and 24 that the discounted shares he bought in Innate Immunotherapeutics Ltd., an Australian medical biotechnology company, “were available to every single individual that was an investor at the time.” (Grimaldi, 1/30)